Who Paid My Doc
Elquis Castillo
Medical Oncology Gadsden, AL Medical Doctor
NPI 1609890474 CMS profile 28118
705 Goodyear Ave, Gadsden, AL 35903
General payments
$2,523
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Elquis Castillo of Gadsden, AL is reported in the CMS Open Payments database as having received $2,523 across 33 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 43rd percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $363 | 3 | |
| 2024 | General | $17 | 1 | |
| 2023 | General | $707 | 9 | |
| 2021 | General | $27 | 2 | |
| 2020 | General | $351 | 3 | |
| 2019 | General | $1,059 | 15 |
Beside peers
- Elquis Castillo
- Medical Oncology median
- Middle half of Medical Oncology
- National median
In program year 2025, general payments to Elquis Castillo were reported at $363. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.
Show as a table
| Year | Elquis Castillo | Medical Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,059 | $968 | $140–$6,658 | $163 |
| 2020 | $351 | $747 | $102–$5,891 | $114 |
| 2021 | $27 | $430 | $50–$4,098 | $132 |
| 2022 | $0 | $812 | $127–$4,907 | $149 |
| 2023 | $707 | $957 | $144–$5,248 | $160 |
| 2024 | $17 | $1,042 | $149–$5,650 | $164 |
| 2025 | $363 | $1,128 | $147–$5,675 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 71 drugsPart D claims
3,806
Drug cost
$9,025,713
Branded share of claims
30.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Kisqali Ribociclib Succinate | Brand | 110 | $1,355,596 | |
| Jakafi Ruxolitinib Phosphate | Brand | 78 | $1,130,951 | |
| Brukinsa Zanubrutinib | Brand | 67 | $983,018 | |
| Imbruvica Ibrutinib | Brand | 61 | $808,777 | |
| Lenalidomide | Generic | 57 | $659,664 | |
| Ibrance Palbociclib | Brand | 33 | $502,629 | |
| Revlimid Lenalidomide | Brand | 29 | $477,779 | |
| Pomalyst Pomalidomide | Brand | 20 | $453,911 | |
| Calquence Acalabrutinib Maleate | Brand | 25 | $377,166 | |
| Lenvima Lenvatinib Mesylate | Brand | 15 | $364,626 |
The 10 drugs with the highest cost, of 71 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 117 billing codesPaid by Medicare
$5,381,223
Medicare patients
692
Services billed
229,655
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 56% | |
| Cancer | 47% | |
| Chronic kidney disease | 43% | |
| Diabetes | 40% | |
| Ischemic heart disease | 39% | |
| Depression | 32% | |
| COPD | 31% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 35 | 41,800 | $1,860,096 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 | Office | 15 | 13,224 | $486,801 |
| Injection, ferric derisomaltose, 10 mg J1437 | Office | 124 | 17,100 | $268,299 |
| Injection, denosumab, 1 mg J0897 | Office | 35 | 9,300 | $190,943 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units J0885 | Office | 25 | 7,520 | $48,117 |
| Injection, fulvestrant, 25 mg J9395 | Office | 12 | 1,980 | $12,228 |
| Injection, epoetin alfa, biosimilar, (retacrit) (for non-esrd use), 1000 units Q5106 | Office | 15 | 1,480 | $8,839 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) Q0138 | Office | 14 | 12,750 | $3,165 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 67 | 594 | $2,822 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 44 | 2,370 | $1,685 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
33 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Medical Oncology in Alabama
Practitioners in the same specialty and state, ranked by reported value.
All Medical Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Alabama
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.